Lifeline Biotechnologies, Inc. Positioned for Continued Breast Cancer System Development and Advancement

RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (OTCPK: LLBT) announced today that the recent capital restructuring has positioned the Company to continue the development of its First Warning System™, which is designed to assist in the early detection of breast cancer.

Jim Holmes, Lifeline's CEO, stated, "Nanyang Technical University (NTU) in Singapore will lead the continued improvement of Lifeline's proprietary software. The new advancements in the software will allow it to classify women who have periodic breast examinations. The classifications are expected to identify normal, suspicious and positive ranges for breast cancer."

Dr. Louis Keith, Lifeline's Medical Director, said, "We have worked with NTU for the last two years. They have, on a preliminary basis using patient data previously provided by Lifeline, increased the efficiency of our interpretive software. They will now review additional patient data. It is our expectation, based on the results of their preliminary findings, that they will upgrade our software, which is expected to produce acceptable levels of interpretation needed in order to commercialize the process."

About Lifeline Biotechnologies, Inc:

The Company is focused on completing the development of the First Warning System™, designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System™ is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year providing a potential savings of up to $2.8 billion annually. The First Warning System™ could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance. Upon the completion of the aforementioned steps, Lifeline will commence marketing its early breast cancer detection system. Management's current and best estimate is that the required steps could take two to four years to conclude. The future value of the Company could be dependent upon these successes. Lifeline competes in the capital markets for financing. The financial markets are very competitive and dilution has occurred as a result of previous funding and may occur again in order to secure future capital. More information is available at the Company's Web site: www.lbti.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:

Lifeline Biotechnologies
Investor Relations
866-THE APPL(E)
www.lbti.com